The Best of IMS

October 7 - November 4, 2026 - Webinar Series
The International Myeloma Society (IMS) is please to announce our “Best of IMS Series” a curated collection of the most significant insights and key breakthroughs from our annual meeting. This series of four webinars for our audiences in East Coast, West Coast, Europe, and Asia Pacific. 

 

 

Practical Insights into and Translational Aspects of Novel Immune Therapies in Multiple Myeloma

October 12, 2026 - Vienna, Austria
This high-impact educational program, held in conjunction with the DGHO Annual Meeting, seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.
Not attending the DGHO Annual Meeting? Select the “On-demand Registration” option to receive access to the recording approximately 3 weeks post-meeting.
Our sponsors:
Platinum
Gold
Silver

8th Immune Effector Cell Therapies in Multiple Myeloma Workshop

March 19 - 20, 2027 - Boston Marriott Long Wharf, Boston, MA

Save the date for the 8th Immune Effector Cell Therapies in Multiple Myeloma Workshop – March 19-20, 2027.

More details will be released soon!

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events

  • This field is for validation purposes and should be left unchanged.